drugset / Trial / NCT01485770

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

NCT01485770

Phase 2 Completed 33 enrolled Jazz Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

Timeline

Start
2011-12
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Solriamfetol Small molecule 300 mg Oral

Indications